Advertisement
Advertisement
U.S. Markets open in 5 hrs 16 mins
Advertisement
Advertisement
Advertisement
Advertisement

BioCorRx Inc. (BICX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.4200+0.6200 (+22.14%)
At close: 3:41PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.8000
Open3.2700
BidN/A x N/A
AskN/A x N/A
Day's Range3.2700 - 3.4900
52 Week Range0.1550 - 8.1000
Volume1,992
Avg. Volume1,555
Market Cap22.635M
Beta (5Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)-0.7190
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.65
  • GlobeNewswire

    BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant

    ANAHEIM, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has filed a patent application with the Russian Patent Office (Rospatent) for a biodegradable implant including naltrexone. Several of the claims in the application are intended to cover BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid u

  • Zacks Small Cap Research

    BICX: New Grant, Patent Filed

    By Beth Senko, CFA OTC:BICX READ THE FULL BICX RESEARCH REPORT BioCorRx, Inc. (OTC:BICX) is at an early point in front of a vast market opportunity for medication assisted treatment (MAT) of opioid and alcohol use disorders. In September, the Company received a $3.5 million grant to support further development and clinical trials of its subcutaneous pellet of naltrexone (BICX104). Trials are

  • GlobeNewswire

    BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th

    ANAHEIM, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it will be presenting at LD Micro’s 14th annual Main Event on Tuesday, October 12, 2021, at 1:30 PM PT/4:30 PM ET at the Luxe Sunset Bel-Air in Los Angeles. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., and Brady Granier, President and Director, CEO of BioCorRx Pha

Advertisement
Advertisement